| URL | https://www.thomasnet.com/insights/reshoring-medic |
| Source | thomasnet.com |
| Date Published | 06/11/2025 |
| Author Name | Laura Ross |
| Company/Division name | Scorpion Therapeutics |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 500 |
| Year reshoring announced: | 2025 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 650 |
| City reshored to: | Manhattan |
| State(s) reshored to: | KS |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | bio pharma |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |